Pricing Log in Create free account
Friday 6 November 2026 Export TFX’s income statement to Excel — free account

Teleflex Incorporated

TFX Healthcare Medical Instruments & Supplies

Teleflex Incorporated’s revenue for fiscal 2025 (year ended December 2025) was $2.0 billion, up 17.2% from fiscal 2024.

Revenue
+28.9%
EPS
−17.3%
Free cash flow
+220.1%
Total debt
+47.7%

Quarter to June 2026, against a year earlier

152.16 2.29 +1.53%
Market cap
$6.5B
P/E
0.0×
Fwd P/E
37.4×
Dividend yield
0.89%
F-score
5/9
Altman Z
2.04
Beneish M
−2.21
Dividend safety
20/100
Overview Business Profile Earnings & Analysis
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios
Segments Valuation Filings

Teleflex Incorporated 10-K filed Feb 27, 2026

Fiscal year 2025 · Period ended Dec 31, 2025 · Filed · accepted 4:11 PM ET · Document on sec.gov · Filing index

What changed

Item 1, Business Item 1A, Risk Factors Item 7, Management’s Discussion and Analysis

Item 1, Business, against the 10-K filed Feb 28, 2025: 12 added · 17 removed · 35 modified; 3 with only figures updated

  1. Removed · HISTORY AND RECENT DEVELOPMENTS

    In 2017, we completed two large scale acquisitions: NeoTract, Inc. ("NeoTract") and Vascular Solutions, Inc. (“Vascular Solutions”). NeoTract was a medical device company that developed and commercialized the UroLift System, a minimally invasive medical device for treating lower urinary tract symptoms due to benign prostatic